<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(10)</volume><submitter>Kille A</submitter><pubmed_abstract>Dual anti-platelet therapy (DAPT) with clopidogrel and acetylsalicylic acid (ASA) has previously been recommended after transcatheter aortic valve implantation (TAVI) and is still the standard of care in patients who underwent coronary stent placement within 3 months prior to TAVI. This study sought to evaluate whether on-treatment platelet reactivity is a predictor for the occurrence of bleeding events after TAVI. This study enrolled 484 patients undergoing TAVI from November 2013 until April 2018. Patients were either on long-term DAPT with clopidogrel and ASA or received loading doses of both drugs before TAVI, reflecting the standard of care at the time of the patient's enrollment. Platelet reactivity was determined by multi-electrode impedance aggregometry before TAVI, at days 1 and 5</pubmed_abstract><journal>Journal of clinical medicine</journal><pagination>2871</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9148071</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Impact of On-Clopidogrel Platelet Reactivity on Incidence of Peri-Interventional Bleeding in Patients Undergoing Transcatheter Aortic Valve Implantation.</pubmed_title><pmcid>PMC9148071</pmcid><pubmed_authors>Franke K</pubmed_authors><pubmed_authors>Neumann FJ</pubmed_authors><pubmed_authors>Hochholzer W</pubmed_authors><pubmed_authors>Valina CM</pubmed_authors><pubmed_authors>Corpataux N</pubmed_authors><pubmed_authors>Kille A</pubmed_authors><pubmed_authors>Hromek J</pubmed_authors><pubmed_authors>Nuhrenberg TG</pubmed_authors><pubmed_authors>Trenk D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Impact of On-Clopidogrel Platelet Reactivity on Incidence of Peri-Interventional Bleeding in Patients Undergoing Transcatheter Aortic Valve Implantation.</name><description>Dual anti-platelet therapy (DAPT) with clopidogrel and acetylsalicylic acid (ASA) has previously been recommended after transcatheter aortic valve implantation (TAVI) and is still the standard of care in patients who underwent coronary stent placement within 3 months prior to TAVI. This study sought to evaluate whether on-treatment platelet reactivity is a predictor for the occurrence of bleeding events after TAVI. This study enrolled 484 patients undergoing TAVI from November 2013 until April 2018. Patients were either on long-term DAPT with clopidogrel and ASA or received loading doses of both drugs before TAVI, reflecting the standard of care at the time of the patient's enrollment. Platelet reactivity was determined by multi-electrode impedance aggregometry before TAVI, at days 1 and 5</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2026-04-08T10:13:50.796Z</modification><creation>2025-04-04T13:30:24.894Z</creation></dates><accession>S-EPMC9148071</accession><cross_references><pubmed>35628999</pubmed><doi>10.3390/jcm11102871</doi></cross_references></HashMap>